Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

a more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as posterior uveitis, retinal vasculitis and vascular, neurological and gastrointestinal ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases; Initial data for NKX ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimm ...

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

Rheumatoid Vasculitis Neuropathy can also develop from ... Dr. Biggee brings a human-centered approach to wellness rather than focusing solely on diseases. Dr. Biggee graduated cum laude with ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

It is often associated with ANCA-associated vasculitis, an autoimmune condition ... and patient-first approach played a vital role in saving this young woman’s kidneys—and possibly her life.